You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!
Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 10
Intercept to Present at Upcoming Investor Conferences in May
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conferences: Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV at 11:20 a.m. PT on Tuesday, May 14, 2019 in Las Vegas, NV at 11:20 a.m. PT on Tuesday, May 14, 2019 UBS Globa...
Yahoo FinanceMay 9
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
Intercept Pharmaceuticals, Inc. ICPT gained 3.02% after the company posted mixed results for the first quarter. The company reported a wider-than-expected loss but beat on sales expectations. The company incurred a loss of $3.03 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $2.57 but narrower than the year-ago loss of $3.22. Quarterly revenues were $52.2 million, up from $35.9 million in the year-ago quarter. Revenues also marginally surpassed the Zacks Consensus Est...
Yahoo FinanceMay 9
2 Reasons Intercept Pharmaceuticals Stock Tanked in April
What happened Intercept Pharmaceuticals (NASDAQ: ICPT), a commercial-stage liver disease specialist, lost a staggering 22.7% of its value in April, according to data from S&P Global Market Intelligence. What caused investors to hit the exits last month? Intercept's shares broke down in April for two reasons: Scroll to continue with content Ad The raging drug pricing debate in the United States weighed on nearly every biopharma stock last month. Not surprisingly, Intercept's shares proved to be no except...
-$2.52 per share
-$3.03 per share